| Company Name: |
DebyeTec.com Inc. |
| Tel: |
18086626237 18086626237 |
| Email: |
2693528373@qq.com |
|
| | 8-OH-DPAT·hydrobromide Basic information |
| Product Name: | 8-OH-DPAT·hydrobromide | | Synonyms: | 3-(Dipropylamino)tetralin-5-ol·hydrobrominate;Serotonin agonist DPAT;rac-8-Hydroxy-2-dipropylaMinotetralin HydrobroMide;(+/-)-8-Hydroxy(N,N-dipropyl-2-aMino)tetralin HydrobroMide;7-(DipropylaMino)-5,6,7,8-tetrahydro-1-naphthalenol HydrobroMide;8-OH-DPAT HRr;7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol hydrobromide;7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol hydrobromide76135-31-4 | | CAS: | 76135-31-4 | | MF: | C16H25NO.BrH | | MW: | 328.29 | | EINECS: | | | Product Categories: | Agonist;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 76135-31-4.mol |  |
| | 8-OH-DPAT·hydrobromide Chemical Properties |
| | 8-OH-DPAT·hydrobromide Usage And Synthesis |
| Uses | Dopamine receptor Agonist. | | Biological Activity | The standard selective 5-HT1A agonist. Also has moderate affinity for 5-HT7 receptors (pKi is 6.6 at the human 5-HT7 receptor expressed in HEK 293 cells). Reduces hippocampal 5-HT levels following systemic administration in rats in vivo. | | in vivo | 8-OH-DPAT (8-Hydroxy-DPAT) hydrobromide (32, 56, 80, 100 mg/kg; intramuscularly; 15 min prior to the testing session) of the highest dose significantly interferes with sustained attention and reinforcer efficacy (progressive ratio; PR) performance in the 3,4-methylenedioxymethamphetamine (MDMA)-exposed but not control animals[1].
| | IC 50 | 5-HT1A Receptor: 8.19 (pIC50) | | storage | Desiccate at +4°C |
| | 8-OH-DPAT·hydrobromide Preparation Products And Raw materials |
|